Imperial College London
Alternate

Emeritus ProfessorKimFox

Faculty of Medicine, National Heart & Lung Institute

Emeritus Professor
 
 
 
//

Contact

 

+44 (0)20 7594 7966kim.fox

 
 
//

Assistant

 

Ms Deborah Curcher +44 (0)20 7594 7966

 
//

Location

 

Guy Scadding BuildingRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Ferrari:2020:10.1016/S0140-6736(20)31790-6,
author = {Ferrari, R and Ford, I and Fox, K and Challeton, JP and Correges, A and Tendera, M and Widimsky, P and Danchin, N},
doi = {10.1016/S0140-6736(20)31790-6},
journal = {The Lancet},
pages = {830--838},
title = {The efficacy and safety of trimetazidine in patients having been treated by percutaneous coronary intervention (ATPCI): Results of a randomised double-blind placebo-controlled trial},
url = {http://dx.doi.org/10.1016/S0140-6736(20)31790-6},
volume = {396},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundAngina might persist or reoccur despite successful revascularisation with percutaneous coronary intervention (PCI) and antianginal therapy. Additionally, PCI in stable patients has not been shown to improve survival compared with optimal medical therapy. Trimetazidine is an antianginal agent that improves energy metabolism of the ischaemic myocardium and might improve outcomes and symptoms of patients who recently had a PCI. In this study, we aimed to assess the long-term potential benefits and safety of trimetazidine added to standard evidence-based medical treatment in patients who had a recent successful PCI.MethodsWe did a randomised, double-blind, placebo-controlled, event-driven trial of trimetazidine added to standard background therapy in patients who had undergone successful PCI at 365 centres in 27 countries across Europe, South America, Asia, and north Africa. Eligible patients were aged 21–85 years and had had either elective PCI for stable angina or urgent PCI for unstable angina or non-ST segment elevation myocardial infarction less than 30 days before randomisation. Patients were randomly assigned by an interactive web response system to oral trimetazidine 35 mg modified-release twice daily or matching placebo. Participants, study investigators, and all study staff were masked to treatment allocation. The primary efficacy endpoint was a composite of cardiac death; hospital admission for a cardiac event; recurrence or persistence of angina requiring an addition, switch, or increase of the dose of at least one antianginal drug; or recurrence or persistence of angina requiring a coronary angiography. Efficacy analyses were done according to the intention-to-treat principle. Safety was assessed in all patients who had at least one dose of study drug. This study is registered with the EU Clinical Trials Register (EudraCT 2010-022134-89).FindingsFrom Sept 17, 2014, to June 15, 2016, 6007 patients were enrolled and randomly assigned to receiv
AU  - Ferrari,R
AU  - Ford,I
AU  - Fox,K
AU  - Challeton,JP
AU  - Correges,A
AU  - Tendera,M
AU  - Widimsky,P
AU  - Danchin,N
DO  - 10.1016/S0140-6736(20)31790-6
EP  - 838
PY  - 2020///
SN  - 0140-6736
SP  - 830
TI  - The efficacy and safety of trimetazidine in patients having been treated by percutaneous coronary intervention (ATPCI): Results of a randomised double-blind placebo-controlled trial
T2  - The Lancet
UR  - http://dx.doi.org/10.1016/S0140-6736(20)31790-6
UR  - https://www.sciencedirect.com/science/article/pii/S0140673620317906?via%3Dihub
UR  - http://hdl.handle.net/10044/1/82242
VL  - 396
ER  -
Download